Inhibition of nuclear factor kappa B (NFκB) activity in oral tumor cells prevents depletion of NK cells and increases their functional activation

Cancer Immunology, Immunotherapy

Volumn 55, Issue 9, 2006, Pages 1052-1063

  Jewett, Anahid ^a,b   Cacalano, Nicholas A ^a   Teruel, Antonia ^a,b   Romero, Marcela ^a,b   Rashedi, Marjan ^a,b   Wang, Meiying ^a,b   Nakamura, Hiromi ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Apoptosis; IFN ; IL 6; Natural killer; NF B; NK; TNF

Indexed keywords

CD69 ANTIGEN; GAMMA INTERFERON; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; RECOMBINANT INTERLEUKIN 6; REPRESSOR PROTEIN;

ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL ACTIVATION; CELL FUNCTION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; EFFECTOR CELL; GENETIC TRANSFECTION; HEP 2 CELL; HUMAN; HUMAN CELL; MOUTH TUMOR; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; TUMOR CELL;

ANTIGENS, CD; ANTIGENS, DIFFERENTIATION, T-LYMPHOCYTE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; COCULTURE TECHNIQUES; GENE TRANSFER TECHNIQUES; HUMANS; I-KAPPA B PROTEINS; INTERFERON TYPE II; INTERLEUKIN-6; KILLER CELLS, NATURAL; LARYNGEAL NEOPLASMS; LYMPHOCYTE ACTIVATION; MOUTH NEOPLASMS; NF-KAPPA B; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 33744486052     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-005-0093-7     Document Type: Article

References (54)

1. Castiglione F, Destefanis M, Marenco D, Gosso P, Manera G, Porcile G. (1996) The mammographic screening project in 2 local health units of Piemonte. Epidemiol Prev 20:157
2. Veltri RW, Rodman SM, Maxim PE, Baseler MW, Sprinkle PM (1986) Immune complexes, serum proteins, cell-mediated immunity, and immune regulation in patients with squamous cell carcinoma of the head and neck. Cancer 57:2295
3. Schantz SP, Shillitoe EJ, Brown B, Campbell B (1986) Natural killer cell activity and head and neck cancer: a clinical assessment. J Natl Cancer Inst 77:869
4. Marrogi AJ, Munshi A, Merogi AJ, Ohadike Y, El-Habashi A, Marrogi OL, Freeman SM (1997) Study of tumor infiltrating lymphocytes and transforming growth factor-beta as prognostic factors in breast carcinoma. Int J Cancer 74:492
5. Camp BJ, Dyhrman ST, Memoli VA, Mott LA, Barth RJ Jr (1996) In situ cytokine production by breast cancer tumor-infiltrating lymphocytes. Ann Surg Oncol 3:176
6. Hartveit F (1998) Breast cancer: poor short-term prognosis in cases with moderate lymphocyte infiltration at the tumour edge: a preliminary report. Oncol Rep 5:423
7. Gimmi CD, Morrison BW, Mainprice BA, Gribben JG, Boussiotis VA, Freeman GJ, Park SY, Watanabe M, Gong J, Hayes DF, Kufe DW, Nadler LM (1996) Breast cancer-associated antigen, DF3/MUC1, induces apoptosis of activated human T cells. Nat Med 2:1367
8. Kolenko V, Wang Q, Riedy MC, O'Shea J, Ritz J, Cathcart MK, Rayman P, Tubbs R, Edinger M, Novick A, Bukowski R, Finke J (1997) Tumor-induced suppression of T lymphocyte proliferation coincides with inhibition of Jak3 expression and IL-2 receptor signaling: role of soluble products from human renal cell carcinomas. J Immunol 159:3057
9. Mulder WM, Bloemena E, Stukart MJ, Kummer JA, Wagstaff J, Scheper RJ (1997) T cell receptor-zeta and granzyme B expression in mononuclear cell infiltrates in normal colon mucosa and colon carcinoma. Gut 40:113
10. Hayry P, Totterman. TH (1978) Cytological and functional analysis of inflammatory infiltrates in human malignant tumors I Composition of the inflammatory infiltrates. Eur J Immunol 8:866
11. Miescher S, Stoeck M, Qiao L, Barras C, Barrelet L, von Fliedner V (1988) Preferential clonogenic deficit of CD8-positive T-lymphocytes infiltrating human solid tumors. Cancer Res 48:6992
12. Qin J, Han B, Pang J (1997) The relationship between TIL from human primary hepatic carcinoma and prognosis. Zhonghua Yi Xue Za Zhi 77:167
13. Han X, Papadopoulos AJ, Ruparelia V, Devaja O, Raju KS (1997) Tumor lymphocytes in patients with advanced ovarian cancer: changes during in vitro culture and implications for immunotherapy. Gynecol Oncol 65:391
14. Itoh K, Tilden AB, Balch CM (1986) Interleukin 2 activation of cytotoxic T-lymphocytes infiltrating into human metastatic melanomas. Cancer Res 46:3011
15. Jewett A, Bonavida B (1996) Target-induced inactivation and cell death by apoptosis in a subset of human NK cells. J Immunol 156:907
16. Lanier LL (2000) Turning on natural killer cells. J Exp Med 191:1259
17. Baeuerle PA, Baltimore D (1996) NF-kappa B: ten years after. Cell 87:13
18. Andela VB, Schwarz EM, Puzas JE, O'Keefe RJ, Rosier RN (2000) Tumor metastasis and the reciprocal regulation of prometastatic and antimetastatic factors by nuclear factor kappaB. Cancer Res 60:6557
19. Mukhopadhyay T, Roth JA, Maxwell SA (1995) Altered expression of the p50 subunit of the NF-kappa B transcription factor complex in non-small cell lung carcinoma. Oncogene 11:999
20. Nakshatri H, Bhat-Nakshatri P, Martin DA, Goulet RJ Jr, Sledge GW Jr (1997) Constitutive activation of NF-kappaB during progression of breast cancer to hormone-independent growth. Mol Cell Biol 17:3629
21. Wang W, Abbruzzese JL, Evans DB, Larry L, Cleary KR, Chiao PJ (1999) The nuclear factor-kappa B RelA transcription factor is constitutively activated in human pancreatic adenocarcinoma cells. Clin Cancer Res 5:119
22. Sasaki N, Morisaki T, Hashizume K, Yao T, Tsuneyoshi M, Noshiro H, Nakamura K, Yamanaka T, Uchiyama A, Tanaka M, Katano M (2001) Nuclear factor-kappaB p65 (RelA) transcription factor is constitutively activated in human gastric carcinoma tissue. Clin Cancer Res 7:4136
23. McNulty SE, Tohidian NB, Meyskens FL Jr. 2001. RelA, p50 and inhibitor of kappa B alpha are elevated in human metastatic melanoma cells and respond aberrantly to ultraviolet light B. Pigment Cell Res 14:456
24. Nakayama H, Ikebe T, Beppu M, Shirasuna K (2001) High expression levels of nuclear factor kappaB, IkappaB kinase alpha and Akt kinase in squamous cell carcinoma of the oral cavity. Cancer 92:3037
25. Van Antwerp DJ, Martin SJ, Kafri T, Green DR, Verma IM (1996) Suppression of TNF-alpha-induced apoptosis by NF-kappaB. Science 274:787
26. Baeuerle PA, Henkel T (1994) Function and activation of NF-kappa B in the immune system. Annu Rev Immunol 12:141
27. Thanos D, Maniatis T (1995) NF-kappa B: a lesson in family values. Cell 80:529
28. Jewett A, Wang MY, Teruel A, Poupak Z, Bostanian Z, Park NH (2003) Cytokine dependent inverse regulation of CD54 (ICAM1) and major histocompatibility complex class I antigens by nuclear factor kappaB in HEp2 tumor cell line: effect on the function of natural killer cells. Hum Immunol 64:505
29. Greten FR, Karin M (2004) The IKK/NF-kappaB activation pathway-a target for prevention and treatment of cancer. Cancer Lett 206:193
30. Santos M, Perez P, Segrelles C, Ruiz S, Jorcano JL, Paramio JM (2003) Impaired NF-kappa B activation and increased production of tumor necrosis factor alpha in transgenic mice expressing keratin K10 in the basal layer of the epidermis. J Biol Chem 278:13422
31. Pasparakis M, Courtois G, Hafner M, Schmidt-Supprian M, Nenci A, Toksoy A, Krampert M, Goebeler M, Gillitzer R, Israel A, Krieg T, Rajewsky K, Haase I (2002) TNF-mediated inflammatory skin disease in mice with epidermis-specific deletion of IKK2. Nature 417:861
32. Lukacher AE (2002) IFN-gamma suspends the killing license of anti-tumor CTLs. J Clin Invest 110:1407
33. DiDonato J, Mercurio F, Rosette C, Wu-Li J, Suyang H, Ghosh S, Karin M (1996) Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation. Mol Cell Biol 16:1295
34. Jewett A, Cavalcanti M, Bonavida B, (1997) Pivotal role of endogenous TNF-alpha in the induction of functional inactivation and apoptosis in NK cells. J Immunol 159:4815
35. Rayet B, Gelinas C (1999) Aberrant rel/nfkb genes and activity in human cancer. Oncogene 18:6938
36. Seitz CS, Lin Q, Deng H, Khavari PA, (1998) Alterations in NF-kappaB function in transgenic epithelial tissue demonstrate a growth inhibitory role for NF-kappaB. Proc Natl Acad Sci USA 95:2307
37. Dajee M, Lazarov M, Zhang JY, Cai T, Green CL, Russell AJ, Marinkovich MP, Tao S, Lin Q, Kubo Y, Khavari PA (2003) NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421:639
38. van Hogerlinden M, Rozell BL, Toftgard R, Sundberg JP, (2004) Characterization of the progressive skin disease and inflammatory cell infiltrate in mice with inhibited NF-kappaB signaling. J Invest Dermatol 123:101
39. Perkins ND (2004) NF-kappaB: tumor promoter or suppressor? Trends Cell Biol 14:64
40. Aggarwal BB (2004) Nuclear factor-kappaB: the enemy within. Cancer Cell 6:203
41. van Hogerlinden M, Rozell BL, Ahrlund-Richter L, Toftgard R (1999) Squamous cell carcinomas and increased apoptosis in skin with inhibited Rel/nuclear factor-kappaB signaling. Cancer Res 59:3299
42. Thomas GR, Chen Z, Leukinova E, Van Waes C, Wen J (2004) Cytokines IL-1 alpha, IL-6, and GM-CSF constitutively secreted by oral squamous carcinoma induce down-regulation of CD80 costimulatory molecule expression: restoration by interferon gamma. Cancer Immunol Immunother 53:33
43. St John MA, Li Y, Zhou X, Denny P, Ho CM, Montemagno C, Shi W, Qi F, Wu B, Sinha U, Jordan R, Wolinsky L, Park NH, Liu H, Abemayor E, Wong DT (2004) Interleukin 6 and interleukin 8 as potential biomarkers for oral cavity and oropharyngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg 130:929
44. Diehl S, Rincon M (2002) The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol 39:531
45. Wang T, Niu G, Kortylewski M, Burdelya L, Shain K, Zhang S, Bhattacharya R, Gabrilovich D, Heller R, Coppola D, Dalton W, Jove R, Pardoll D, Yu H (2004) Regulation of the innate and adaptive immune responses by Stat-3 signaling in tumor cells. Nat Med 10:48
46. Morrison BE, Park SJ, Mooney JM, Mehrad B (2003) Chemokine-mediated recruitment of NK cells is a critical host defense mechanism in invasive aspergillosis. J Clin Invest 112:1862
47. Dorner BG, Scheffold A, Rolph MS, Huser MB, Kaufmann SH, Radbruch A, Flesch IE, Kroczek RA (2002) MIP-1alpha, MIP-1beta, RANTES, and ATAC/lymphotactin function together with IFN-gamma as type 1 cytokines. Proc Natl Acad Sci U S A 99:6181
48. Giovannucci E, Egan KM, Hunter DJ, Stampfer MJ, Colditz GA, Willett WC, Speizer FE (1995) Aspirin and the risk of colorectal cancer in women. N Engl J Med 333:609
49. Kopp E, Ghosh S (1994) Inhibition of NF-kappa B by sodium salicylate and aspirin. Science 265:956
50. Grilli M, Pizzi M, Memo M, Spano P (1996) Neuroprotection by aspirin and sodium salicylate through blockade of NF-kappaB activation. Science 274:1383
51. Yin MJ, Yamamoto Y, Gaynor RB (1998) The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature 396:77
52. Thun MJ, Namboodiri MM, Heath CW Jr (1991) Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 325:1593
53. Suh O, Mettlin C, Petrelli NJ (1993) Aspirin use, cancer, and polyps of the large bowel. Cancer 72:1171
54. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Stolley PD, Shapiro S (1991) A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 83:355